Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Tauer

Nurse Practitioner, Gerontology Beverly Hills, CA Nurse Practitioner

NPI 1396218236 CMS profile 10510994

8767 Wilshire Blvd, Ste 201, Beverly Hills, CA 90211

Open in the dashboard

General payments

$6,062

250 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Tauer of Beverly Hills, CA is reported in the CMS Open Payments database as having received $6,062 across 250 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76 3
2024 General $271 3
2023 General $1,887 75
2022 General $2,485 100
2021 General $1,343 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Tauer
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Melissa Tauer were reported at $76. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Melissa Tauer Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,343 $133 $44–$396 $132
2022 $2,485 $142 $48–$452 $149
2023 $1,887 $158 $53–$482 $160
2024 $271 $171 $55–$533 $164
2025 $76 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Jazz Pharmaceuticals Inc. $699 23 payments
  2. GlaxoSmithKline, LLC. $665 33 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $632 31 payments
  4. Harmony Biosciences LLC $569 22 payments
  5. Genzyme Corporation $405 7 payments
  6. Novartis Pharmaceuticals Corporation $360 16 payments
  7. Grifols USA, LLC $323 11 payments
  8. Regeneron Healthcare Solutions, Inc. $317 11 payments
  9. Amgen Inc. $301 13 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $277 13 payments
  11. Other $1,516 70 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,781 247 payments
  2. Education $281 3 payments
Products named General payments · program years 2021–2025
  1. XYWAV $570 20 payments
  2. DUPIXENT Immunology $505 8 payments
  3. Kerendia $417 22 payments
  4. Prolastin-C Liquid $323 11 payments
  5. DUPIXENT Inflammation And Immunology $317 11 payments
  6. WAKIX Sleep Medicine $316 15 payments
  7. NUCALA $307 15 payments
  8. TEZSPIRE $273 11 payments
  9. Wakix Neurological Disorders $253 7 payments
  10. TRELEGY ELLIPTA $235 11 payments
  11. Other $2,841 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

204

Median for Nurse Practitioner: 389

Drug cost

$3,182

Median for Nurse Practitioner: $21,885

Branded share of claims

41.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Paxlovid Nirmatrelvir/Ritonavir Brand 17 $1,429
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $514
Fluticasone Propionate Generic 46 $437
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 26 $230
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 24 $186
Methylprednisolone Generic 16 $108
Naproxen Generic 19 $96
Doxycycline Hyclate Generic 12 $94
Triamcinolone Acetonide Generic 12 $44
Cephalexin Generic 15 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$34,927

Of which drugs: $167

Medicare patients

316

Average age 75

Services billed

669

199 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 59%
Ischemic heart disease 39%
Osteoporosis 34%
Diabetes 25%
Depression 25%
Cancer 23%
Chronic kidney disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
  • JAZZ PHARMACEUTICALS INC. $150
$150 — —
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $100
$100 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

250 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record